Palisade Bio
PALI
6 hedge funds and large institutions have $235K invested in Palisade Bio in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
14% less funds holding
Funds holding: 7 → 6 (-1)
49% less capital invested
Capital invested by funds: $463K → $235K (-$227K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
75% less call options, than puts
Call options by funds: $1K | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$77.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$106K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
-$39K |
| 3 |
VF
Virtu Financial
New York
|
-$15K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$6K |
| 5 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
-$1K |
PALI Hedge Fund Activity: Q2 2019 in Review
6 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q2 2019, worth a combined $235K — down 49% from $463K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PALI and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $77.6K. The largest seller was Sabby Management, exiting entirely with an estimated $106K sold.
- 6 institutional investors held Palisade Bio (PALI) as of Q2 2019, down from 7 in Q1 2019.
- Funds reported $235K of Palisade Bio stock for Q2 2019, down 49% quarter-over-quarter.
- 1 fund opened new Palisade Bio positions in Q2 2019 and 2 closed out, a net change of -1 holder.
- The largest Palisade Bio buyer in Q2 2019 was Renaissance Technologies, an estimated $77.6K added.
- The largest Palisade Bio seller in Q2 2019 was Sabby Management, an estimated $106K sold.
Based on aggregated 13F filings for Q2 2019.